Hefei Lifeon Pharmaceutical Co (SZSE:003020) Cash-to-Debt : 13.68 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Hefei Lifeon Pharmaceutical Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Hefei Lifeon Pharmaceutical Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 13.68.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Hefei Lifeon Pharmaceutical Co could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Hefei Lifeon Pharmaceutical Co's Cash-to-Debt or its related term are showing as below:

SZSE:003020' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.8 Med: 24.22 Max: No Debt
Current: 13.68

During the past 11 years, Hefei Lifeon Pharmaceutical Co's highest Cash to Debt Ratio was No Debt. The lowest was 0.80. And the median was 24.22.

SZSE:003020's Cash-to-Debt is ranked better than
60.03% of 1521 companies
in the Biotechnology industry
Industry Median: 6.39 vs SZSE:003020: 13.68

Hefei Lifeon Pharmaceutical Co Cash-to-Debt Historical Data

The historical data trend for Hefei Lifeon Pharmaceutical Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Hefei Lifeon Pharmaceutical Co Cash-to-Debt Chart

Hefei Lifeon Pharmaceutical Co Annual Data

Trend

Dec13

Dec14

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

9.29

39.70

26.62

47.92

14.70

Hefei Lifeon Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															11.31	59.64	55.07	14.70	13.68

Competitive Comparison of Hefei Lifeon Pharmaceutical Co's Cash-to-Debt

For the Biotechnology subindustry, Hefei Lifeon Pharmaceutical Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hefei Lifeon Pharmaceutical Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hefei Lifeon Pharmaceutical Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Hefei Lifeon Pharmaceutical Co's Cash-to-Debt falls into.

Hefei Lifeon Pharmaceutical Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Hefei Lifeon Pharmaceutical Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	564.449	/	(4.538	+	33.856)
	=	14.70

Hefei Lifeon Pharmaceutical Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	510.239	/	(4.935	+	32.378)
	=	13.67

Hefei Lifeon Pharmaceutical Co (SZSE:003020) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Hefei Lifeon Pharmaceutical Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Hefei Lifeon Pharmaceutical Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Hefei Lifeon Pharmaceutical Co (SZSE:003020) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hefei Lifeon Pharmaceutical Co Ltd (SZSE:003020) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.669, Changjiang West Road, Lifang Factory, Anhui Province, Hefei, CHN, 230088

Website

http://www.lifeon.cn

Hefei Lifeon Pharmaceutial Co Ltd is engaged in the research and development, production and sales of pharmaceutical preparations and raw materials, and the wholesale and retail of pharmaceuticals and medical devices. The main industrial products involve cardiovascular drugs, digestive system drugs, external skin drugs, endocrine system drugs and other fields.

Executives

Wang Qin	Supervisors
Wang Qing	Directors, executives
Xu Xue Yu	Executives

Hefei Lifeon Pharmaceutical Co (SZSE:003020) Headlines

No Headlines